Pioglitazone for Hepatic Steatosis in HIV/Hepatitis C Virus Coinfection

AIDS Research and Human Retroviruses

Volumn 31, Issue 10, 2015, Pages 961-966

  Matthews, Lindsay ^a   Kleiner, David E ^b   Chairez, Cheryl ^c   McManus, Maryellen ^d   Nettles, Mary Jane ^e   Zemanick, Kira ^a   Morse, Caryn Gee ^a   Benator, Debra ^e,f   Kovacs, Joseph A ^a   Hadigan, Colleen ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; BILIRUBIN; CHOLESTEROL; EMTRICITABINE PLUS TENOFOVIR ALAFENAMIDE; GLUCOSE; LAMIVUDINE PLUS ZIDOVUDINE; PIOGLITAZONE; PLACEBO; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL THERAPY; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY WEIGHT DISORDER; CHOLESTEROL BLOOD LEVEL; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FAT CONTENT; FATIGUE; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSURIA; GLYCEMIC CONTROL; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; KIDNEY FAILURE; LUNG ADENOCARCINOMA; MALE; MEDICATION COMPLIANCE; MIXED INFECTION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; POLYDIPSIA; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SORE THROAT; TOOTH ABSCESS; WEIGHT GAIN; WEIGHT REDUCTION; COINFECTION; COMPLICATION; CYTOCHEMISTRY; DIAGNOSTIC IMAGING; LIVER; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RADIOGRAPHY; TREATMENT OUTCOME;

ADULT; COINFECTION; DOUBLE-BLIND METHOD; FATTY LIVER; FEMALE; HEPATITIS C, CHRONIC; HISTOCYTOCHEMISTRY; HIV INFECTIONS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PLACEBOS; RADIOGRAPHY; THIAZOLIDINEDIONES; TREATMENT OUTCOME;

EID: 84941965113     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2015.0093     Document Type: Article

References (27)

1. Jain MK, Skiest DJ, Cloud JW, et al.: Changes in mortality related to human immunodeficiency virus infection: Comparative analysis of inpatient deaths in 1995 and in 1999-2000. Clin Infect Dis 2003;36(8):1030-1038.
2. Sulkowski MS, Mast EE, Seeff LB, and Thomas DL: Hepatitis C virus infection as an opportunistic disease in persons infected with human immunodeficiency virus. Clin Infect Dis 2000;30(Suppl 1):S77-84.
3. Sulkowski MS, Mehta SH, Torbenson M, et al.: Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005;19(6):585-592.
4. Marks KM, Petrovic LM, Talal AH, et al.: Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005;192(11):1943-1949.
5. Bani-Sadr F, Carrat F, Bedossa P, et al.: Hepatic steatosis in HIV-HCV coinfected patients: Analysis of risk factors. AIDS 2006;20(4):525-531.
6. Castera L, Loko MA, Le Bail B, et al.: Hepatic steatosis in HIV-HCV coinfected patients in France: Comparison with HCV monoinfected patients matched for body mass index and HCV genotype. Aliment Pharm Ther 2007;26(11-12):1489-1498.
7. Tanaka A, Uegaki S, Kurihara H, et al.: Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C. World J Gastroenterol 2007;13(39):5180-5187.
8. Patton HM, Patel K, Behling C, et al.: The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol 2004;40(3):484-490.
9. Poynard T, Ratziu V, McHutchison J, et al.: Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology 2003;38(1):75-85.
10. Lok AS, Everhart JE, Chung RT, et al.: Hepatic steatosis in hepatitis C: Comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial. Clin Gastroenterol H 2007;5(2):245-254.
11. Kumar D, Farrell GC, Fung C, and George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002;36(5):1266-1272.
12. Promrat K, Lutchman G, Uwaifo GI, et al.: A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39(1):188-196.
13. Bajaj M, Suraamornkul S, Pratipanawatr T, et al.: Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003;52(6):1364-1370.
14. Belfort R, Harrison SA, Brown K, et al.: A placebocontrolled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006;355(22):2297-2307.
15. Sanyal AJ, Chalasani N, Kowdley KV, et al.: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010;362(18):1675-1685.
16. Rotman Y, Koh C, Zmuda JM, et al.: The association of genetic variability in patatin-like phospholipase domaincontaining protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology 2010;52(3): 894-903.
17. Georgoff P, Thomasson D, Louie A, et al.: Hydrogen-1 MR spectroscopy for measurement and diagnosis of hepatic steatosis. Am J Roentgenol 2012;199(1):2-7.
18. Ishak K, Baptista A, Bianchi L, et al.: Histological grading and staging of chronic hepatitis. J Hepatol 1995;22(6):696-699.
19. Kleiner DE, Brunt EM, Van Natta M, et al.: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41(6):1313-1321.
20. Nan YM, Han F, Kong LB, et al.: Adenovirus-mediated peroxisome proliferator activated receptor gamma overexpression prevents nutritional fibrotic steatohepatitis in mice. Scand J Gastroenterol 2011;46(3):358-369.
21. Cipolletta D, Feuerer M, Li A, et al.: PPAR-gamma is a major driver of the accumulation and phenotype of adipose tissue Treg cells. Nature 2012;486(7404):549-553.
22. Boettcher E, Csako G, Pucino F, et al.: Meta-analysis: Pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis. Aliment Pharm Ther 2012;35(1):66-75.
23. Yki-Jarvinen H, Sutinen J, Silveira A, et al.: Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arterioscl Throm Vasc 2003;23(4):688-694.
24. Marks KM, Kitch D, Chung RT, et al.: Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239. J Acquir Immun Defic Syndr 2014;65(3):345-349.
25. Lemoine M, Barbu V, Girard PM, et al.: Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIVinfected patients. AIDS 2006;20(3):387-395.
26. Zhang W, Wu R, Zhang F, et al.: Thiazolidinediones improve hepatic fibrosis in rats with non-alcoholic steatohepatitis by activating the adenosine monophosphate-activated protein kinase signalling pathway. Clin Exp Pharmacol P 2012;39(12):1026-1033.
27. Zator ZA and Chung RT: After the cure: Management of HCV after achievement of SVR. Curr HIV/AIDS Rep 2013;10(4):428-435.